Answers are grounded in this paper and cite their sources.
Systematic review and meta-analysis demonstrates alpha-mangostin reduces blood glucose in rodent models, suggesting therapeutic potential.
Diabetes mellitus, particularly type 2 diabetes mellitus, is a growing global health burden characterized by chronic hyperglycemia and insulin resistance. Alpha-mangostin (AM), a xanthone from Garcinia mangostana pericarp, exhibits antioxidant, anti-inflammatory, and metabolic regulatory properties in preclinical models. We performed a systematic review and meta-analysis of controlled in vivo studies to assess AM’s anti-hyperglycemic effects. Fourteen studies (25 comparisons) in rodent models of diabetes or hyperglycemia were included. Primary outcome was blood glucose; secondary outcomes were glycated hemoglobin (HbA1c), insulin, and homeostatic model assessment of insulin resistance (HOMA-IR). Random-effects meta-analysis demonstrated that AM significantly reduced fasting blood glucose (mean difference (MD) = −8.75 mmol/L; 95% CI: −10.73 to −6.78; p < 0.001) and HbA1c (MD = −2.20%; 95% CI: −3.07 to −1.32; p < 0.001). AM did not significantly alter circulating insulin (Hedges’ g = 0.43; 95% CI: −0.62 to 1.49; p = 0.42) but improved insulin resistance as measured by HOMA-IR (MD = −0.90; 95% CI: −1.68 to −0.12; p = 0.02). Subgroup, sensitivity, and risk-of-bias analyses supported the robustness of the glucose-lowering association, although substantial between-study heterogeneity was present. Overall, this study provides preclinical evidence that AM exerts significant antihyperglycemic and insulin-sensitizing effects, supporting its potential as a multitarget metabolic modulator. Further standardized and mechanistically informed studies are warranted to facilitate translational progression.
No takes yet. Share an insight, caveat, or question.
Chatatikun et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: